F G Boess
Overview
Explore the profile of F G Boess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boess F, Scelsi M, Grimmer T, Perry R, Tonietto M, Klein G, et al.
J Prev Alzheimers Dis
. 2024 May;
11(3):537-548.
PMID: 38706270
Background: Monoclonal antibodies that target amyloid-beta and remove amyloid plaques can slow cognitive and functional decline in early Alzheimer's disease. Gantenerumab is a subcutaneously administered fully-human anti-amyloid-beta monoclonal antibody with...
2.
Buvat J, Hatzichristou D, Boess F, Buttner H, Gehchan N, Henneges C, et al.
Int J Clin Pract
. 2014 Aug;
68(9):1087-99.
PMID: 25123817
Aims: This was the first observational study evaluating treatment continuation, effectiveness and tolerability of tadalafil 5 mg once daily (TAD-OaD) in patients who chose and paid for treatment of erectile...
3.
Hatzimouratidis K, Buvat J, Buttner H, Vendeira P, Moncada I, Boehmer M, et al.
Int J Impot Res
. 2014 May;
26(6):223-9.
PMID: 24784894
Initiation of ED treatment with a particular PDE5I may influence treatment-adherence and other outcomes. In this multicenter, open-label study, men with ED, naïve to PDE5I, were randomized to tadalafil 5 ...
4.
Steward L, Boess F, Steele J, Liu D, Wong N, Martin I
Mol Pharmacol
. 2000 May;
57(6):1249-55.
PMID: 10825397
The 5-hydroxytryptamine (5-HT)(3) receptor is a member of the ligand-gated ion channel receptor family with significant homology to the nicotinic acetylcholine, gamma-aminobutyric acid(A), and glycine receptors. In this receptor class,...
5.
Bentley J, Bourson A, Boess F, Fone K, Marsden C, Petit N, et al.
Br J Pharmacol
. 1999 May;
126(7):1537-42.
PMID: 10323584
1. The present study examined the effects of the selective 5-HT6 receptor antagonist 4-amino-N-(2, 6 bis-methylamino-pyrimidin-4-yl)-benzene sulphonamide (Ro 04-6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats...
6.
Boess F, CREIGHTON R, Phipps B, McKernan R, Reid J, Martin I
Ann N Y Acad Sci
. 1999 Feb;
861:276-7.
PMID: 9928288
No abstract available.
7.
Boess F, Monsma Jr F, Bourson A, Zwingelstein C, Sleight A
Ann N Y Acad Sci
. 1999 Feb;
861:242-3.
PMID: 9928266
No abstract available.
8.
Sleight A, Boess F, Bos M, Bourson A
Ann N Y Acad Sci
. 1999 Feb;
861:91-6.
PMID: 9928244
Until recently, the majority of actions of the neurotransmitter 5-hydroxytryptamine (5-HT) were generally believed to be mediated by members of the 5-HT1, 5-HT2, 5-HT3 and 5-HT4 receptor families. The application...
9.
Bourson A, Boess F, Bos M, Sleight A
Br J Pharmacol
. 1999 Jan;
125(7):1562-6.
PMID: 9884085
4-Amino-N-(2,4 bis-methylamino-pyrimidin-4-yl) benzene sulphonamide (Ro 04-6790) is a potent, selective and competitive antagonist for the 5-HT6 receptor which can be detected in the cerebro-spinal fluid (CSF) of rats following intraperitoneal...
10.
Boess F, Monsma Jr F, Sleight A
J Neurochem
. 1998 Nov;
71(5):2169-77.
PMID: 9798944
We have examined the ligand binding site of the serotonin 5-HT6 receptor using site-directed mutagenesis. Replacing the highly conserved Asp106 in transmembrane region III by asparagine eliminated D-[3H]-lysergic acid diethylamide...